▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #330 by analyst upside · 2026-11-13
NSRX
Nasus Pharma Ltd.
Healthcare · Market Cap $33M · P/E 0x
ANALYST PRICE TARGET
+485.1%
implied upside to consensus target
Current Price $2.82
Consensus Target $16.5
Bull Target $22.0
Bear Target $7.0
Analysts Covering 4
ANALYST CONSENSUS - STRONG BUY
Strong Buy
4
Buy
0
Hold
0
Sell
0
52-Week Low $1.98
52-Week High $9.5
YTD Return -62.6%
FUNDAMENTALS
Market Cap $33M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.24
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.98
52-Week High $9.5
Current Price $2.82
Bear Target $7.0
Bull Target $22.0
● Now $2.82 ● Target $16.5
TRADING DATA
Avg Volume 17K
YTD Return -62.6%
Analyst Count 4
Consensus Strong Buy
Upside to Target +485.1%
Last Updated 2026-11-13

ANALYST SUMMARY

Nasus Pharma Ltd. (NSRX) is currently trading at $2.82 with a Wall Street consensus price target of $16.5, implying potential upside of 485.1% over the next 12 months. 4 analysts currently cover NSRX, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $22.0, while the most cautious has a target of $7.0.

NSRX operates in the Healthcare sector with a market capitalisation of $33M. The stock is down 62.6% year-to-date and is currently trading near the lower end of its 52-week range of $1.98 – $9.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for NSRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Maxim Group ● Initiated
Buy 2026-10-30 28% win rate (40 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2026-03-26 Building track record
Citizens ● Initiated
Market Outperform 2025-12-18 Building track record
Laidlaw & Co. ● Initiated
Buy 2025-09-29 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →